We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Colchicine (anti-inflammatory)
An ancient anti-inflammatory drug (from autumn crocus) for gout and familial Mediterranean fever, now studied as a geroprotector targeting 'inflammaging.' Randomized trials (LoDoCo2, COLCOT) show low-dose colchicine reduces cardiovascular events in coronary disease — proof that dampening chronic inflammation has real outcome benefit. Lifespan itself is unproven. A prescription drug used off-label, not a supplement.
Prescription medication — not a dietary supplement
Colchicine is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Colchicine doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1974–2026.
Based on 362 studies · 88 meta-analyses · 225 RCTs
Confidence
High confidenceBy outcome
Colchicine is the best RCT-backed test of targeting 'inflammaging' — low-dose colchicine reduced cardiovascular events in LoDoCo2/COLCOT — but the large CLEAR-SYNERGY (OASIS-9) trial found NO benefit after acute MI, so the cardiovascular case is now genuinely contested; there is no lifespan/healthspan trial, and it has a narrow margin with serious interactions.
220 randomised trials
86% were about Colchicine in an audit of 50 of them
Every randomised or controlled trial of Colchicine indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
84 trials ongoing or recruiting · 162 completed on ClinicalTrials.gov
57 of the completed trials have posted results
Registered trials show research momentum for Colchicine, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Colchicine is one of the oldest drugs in continuous use — an alkaloid from the autumn crocus, long used for acute gout and familial Mediterranean fever. It works by binding tubulin and disrupting microtubules, which impairs neutrophil function and inhibits the NLRP3 inflammasome, broadly dampening innate inflammation.
Its geroscience relevance is the concept of 'inflammaging': chronic, low-grade inflammation (driven partly by the NLRP3 inflammasome and senescent-cell secretions) is a hallmark of aging that drives cardiovascular disease, frailty, and neurodegeneration.
Colchicine is the best-evidenced test of whether pharmacologically lowering this inflammation improves hard outcomes — and the answer, at least for the heart, is yes: the randomized LoDoCo and LoDoCo2 trials showed low-dose colchicine (0.5 mg/day) reduced major cardiovascular events in patients with stable coronary disease, and COLCOT showed benefit after myocardial infarction, with meta-analyses confirming the cardiovascular reduction.
This is a genuine, RCT-backed demonstration that targeting inflammaging changes outcomes.
The honest limits: those trials are cardiovascular, not longevity — there is no trial showing colchicine extends lifespan or healthspan broadly; some analyses note more non-cardiovascular deaths/infections, so the net is debated; and colchicine has a narrow therapeutic margin with significant GI side effects (diarrhea), dangerous drug interactions (it is a CYP3A4/P-gp substrate — combining with clarithromycin, certain statins, or grapefruit can cause toxicity), and serious toxicity in overdose.
Colchicine is a prescription drug used off-label for its anti-inflammatory/geroprotective effects; it is not a dietary supplement.
The score reflects real RCT evidence that lowering inflammaging reduces cardiovascular events, against the absence of a longevity trial, a debated net mortality balance, and meaningful toxicity/interactions.
Colchicine binds tubulin and disrupts microtubules, impairing neutrophil chemotaxis and activation — the basis of its anti-inflammatory effect.
It inhibits the NLRP3 inflammasome, lowering IL-1β/IL-6 signaling central to 'inflammaging' and atherosclerosis.
By dampening chronic low-grade inflammation — a hallmark of aging — it addresses a driver of cardiovascular disease, frailty, and neurodegeneration.
How Colchicine works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Avoid or dose-reduce sharply — dangerous CYP3A4/P-gp interaction.
Dose-reduce and monitor — higher toxicity risk.
Used in FMF under specialist care; not for off-label longevity use in pregnancy.
Markedly raise colchicine levels — can cause life-threatening toxicity. A critical interaction.
Additive myopathy/rhabdomyolysis risk with some statins.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: More likely with renal impairment or interacting drugs; monitor for muscle weakness.
Tip: Narrow margin; overdose is a medical emergency — strict dosing and interaction checks.
Colchicine has an evidence score of 3/10 — emerging evidence based on 362 indexed studies, including 1 meta-analysis. An ancient anti-inflammatory drug (from autumn crocus) for gout and familial Mediterranean fever, now studied as a geroprotector targeting 'inflammaging.' Randomized trials (LoDoCo2, COLCOT) show low-dose colchicine reduces cardiovascular events in coronary disease — proof that dampening chronic inflammation has real outcome benefit. Lifespan itself is unproven. A prescription drug used off-label, not a supplement. Representative study: PMID 35033433.
Dosing for Colchicine: Off-label cardiovascular/geroprotective use is low-dose: 0.5 mg once daily (the regimen in the cited LoDoCo and COLCOT trials) under a clinician. Acute gout uses higher short-course dosing. Not an approved longevity regimen; mind the drug interactions. Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for Colchicine — consistent daily use matters more than the time of day. Low once-daily dosing for cardiovascular/anti-inflammatory use; take with food to limit GI upset.
Colchicine should be used with caution — talk to a healthcare provider before taking it. Reported side effects include bone-marrow suppression / severe toxicity (overdose), myopathy / neuromyopathy, diarrhea / GI upset. How often they occur is not established for all of them. Use caution if any of these apply to you: Significant renal or hepatic impairment (with interacting drugs); Concurrent strong CYP3A4/P-gp inhibitors; Pregnancy (relative; specialist-directed in FMF).
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism. Its only head-to-head trial with metformin cited here was a 36-person pilot, which does not show it can replace metformin.
Canakinumab
Too few graded studiesAn injectable anti-interleukin-1β monoclonal antibody (Ilaris), approved for rare periodic fever syndromes. Famous for the landmark CANTOS trial — the first proof that lowering inflammation alone (without touching lipids) cuts cardiovascular events, validating the 'inflammaging' hypothesis. But CANTOS showed NO all-cause-mortality benefit and MORE fatal infections, and the follow-up cancer trials failed. An extremely expensive prescription biologic, not a supplement.
Red Yeast Rice
Likely helpsFermented rice containing natural statins that effectively lower LDL cholesterol — the original statin.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 363 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research